High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis...

Area of Science:

• Neuroimmunology
• Immunology
• Clinical Medicine

Background:

• Multiple Sclerosis (MS) exacerbations involve complex immune system dysregulation.
• Glucocorticosteroids, like methylprednisolone, are standard treatments for MS flares.
• The precise impact of high-dose intravenous methylprednisolone on specific immune cell populations during MS exacerbations requires further elucidation.

Purpose of the Study:

• To investigate the effects of high-dose intravenous methylprednisolone on peripheral immune parameters in patients experiencing multiple sclerosis exacerbations.
• To identify specific changes in B cells, NK cells, and IL-8 producing monocytes following methylprednisolone treatment.

Main Methods:

• Peripheral blood samples were collected from 32 multiple sclerosis patients before and 7 days after initiating high-dose intravenous methylprednisolone therapy.
• Two-color flow cytometry was employed to analyze immune cell populations and cytokine production.

Main Results:

• A significant increase in B cell counts was observed post-treatment.
• A significant decrease in Natural Killer (NK) cell counts was noted.
• Monocytes expressing Interleukin-8 (IL-8) showed a significant reduction after methylprednisolone administration.

Conclusions:

• High-dose intravenous methylprednisolone significantly modulates peripheral immune cell profiles during multiple sclerosis exacerbations.
• The observed changes, particularly the reduction in IL-8 producing monocytes, may contribute to the therapeutic effects of glucocorticosteroids by mitigating blood-brain barrier disruption and immune cell infiltration into the central nervous system.
• These findings enhance our understanding of the immunomodulatory mechanisms of methylprednisolone in multiple sclerosis management.